LG-2527
Chemical compound
From Wikipedia, the free encyclopedia
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer, but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
| Clinical data | |
|---|---|
| Drug class | Progestin; Progestogen |
